What is Noveltreat 2.4 mg Pre-filled Pen

Noveltreat 2.4 mg Pre-filled Pen is a higher-strength once-weekly injectable medication. It is designed for chronic weight management in adults with Obesity or those who are overweight with at least one weight-related condition.

This medication contains an FDA-approved active ingredient, Semaglutide base (2.4 mg/0.75 ml), a Glucagon-like Peptide-1 (GLP-1) receptor agonist that replicates the action of natural incretin hormones. Sun Pharmaceuticals manufactures Noveltreat 2.4 mg in GMP-compliant facilities.

Semaglutide functions through multiple mechanisms. It delays gastric emptying to prolong satiety, acts on brain receptors to reduce hunger signals, and enhances insulin secretion while suppressing glucagon release. These combined effects contribute to reduced food intake, improved glycemic control, and sustainable weight reduction.

The Noveltreat injection is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm on the same day each week. Some of its common side effects are nausea, vomiting, diarrhea, constipation, and stomach pain. They typically subside as treatment continues.

Before initiating Noveltreat, disclose any history of Pancreatitis, thyroid tumors, gallbladder disease, kidney problems, or Diabetic Retinopathy (eye disease caused by Diabetes) to the healthcare provider. Store unopened Noveltreat 2.4 mg Pre-filled Pens refrigerated at 2°C to 8°C.

Once in use, the pen can remain at room temperature below 30°C or stay refrigerated for up to 6 weeks. Always keep the cap on between uses to shield from light, and properly dispose of used pens in an appropriate sharps container.

What are the benefits of taking Noveltreat 2.4 mg Pre-filled Pen

Noveltreat 2.4 mg Pre-filled Pen provides benefits for individuals seeking effective chronic weight management and improved metabolic health. Some of them include:

• Superior weight loss: The 2.4 mg dose delivers better appetite suppression and satiety enhancement, helping achieve clinically meaningful weight reduction when combined with lifestyle modifications.
• Weekly dosing convenience: One injection per week offers better adherence compared to daily treatments.
• Metabolic improvements: Treatment leads to better glycemic control, reduced hemoglobin A1c levels, and better insulin sensitivity, particularly helpful in the case of Type 2 Diabetes.
• Cardiovascular risk reduction: Semaglutide can reduce the risk of events like Stroke, heart attack, and cardiovascular death in patients with existing heart disease.

How to use Noveltreat 2.4 mg Pre-filled Pen

Noveltreat 2.4 mg Pre-filled Pen is a prescription medication requiring medical supervision. Follow these administration instructions carefully:

• Administer Noveltreat once weekly on the same day each week.
• Inject subcutaneously (under the skin) into the abdomen, front of thigh, or upper arm after wiping the area properly.
• It can be administered with or without food, but simple light meals can help prevent nausea.
• Never take more than the prescribed dose or administer it more than once a week. Do not self-administer without proper training or medical guidance.

Strengths and Substitutes

Noveltreat Pre-filled Pen is currently available in a single strength at Cheap Medicine Shop. However, the following effective alternatives are available:

View all substitutes

What are the side effects of Noveltreat 2.4 mg Pre-filled Pen

Like all medications, Noveltreat 2.4 mg Pre-filled Pen can cause mild side effects that usually improve as your body adapts to treatment. Contact a doctor if symptoms persist or become severe:

• Nausea or vomiting
• Diarrhea or constipation
• Abdominal discomfort or pain
• Reduced appetite
• Headache or dizziness
• Fatigue
• Injection site reactions, such as redness or itching

Safety Advice

Liver Disease

Patients with liver disease should use Noveltreat 2.4 mg with appropriate medical supervision. It is vital to disclose pre-existing liver conditions to the healthcare provider to ensure safety.

Kidney Impairment

Exercise caution when using Noveltreat in patients with kidney impairment, especially those with severe dysfunction. While the medication itself doesn't require dose adjustment for mild to moderate kidney disease, gastrointestinal side effects can cause dehydration and potentially worsen kidney problems. Never use the medicine without medical consultation.

Pregnant and Breastfeeding women

Noveltreat 2.4 mg is contraindicated during pregnancy due to potential fetal risks. Stop treatment at least 2 months before planned conception. The transfer of Semaglutide into breast milk remains unknown, so nursing mothers should consult their healthcare provider to evaluate risks versus benefits before initiating or continuing treatment.

Avoid

Avoid Noveltreat in the case of personal or family history of cancers such as Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2), as the medication carries a thyroid tumor risk warning. Do not use it if allergic to Semaglutide. Patients with active or recent Pancreatitis and Type 1 Diabetes should avoid this medication.